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SUMMARY 
Isovaleric acidaemia (IVA) is caused by a deficiency of isovaleryl CoA dehydrogenase. The diagnosis can be 
established biochemically by the demonstration of increased levels of isovalerylglycine (IVG) and 
3-hydroxyisovaleric acid in urine and by the deficiency of incorporation of radiolabel from ['4C]isovaleric acid in 
macromolecules in cultured fibroblasts. This paper reports a consecutive series of 24 prenatal diagnoses in 
pregnancies at high risk, using both methods-metabolite and indirect enzyme assay. Mected fetuses were 
diagnosed in four pregnancies: three in the second trimester and one recent case in the first trimester. The latter 
represents the &st reported case of a kst-trimester diagnosis of IVA by direct analysis of chorionic villi. We also 
report the k s t  demonstration of strongly accumulated IVG in the amniotic fluid in the 12th week of an affected 
pregnancy. 
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INTRODUCTION 
Isovalenc acidaemia (IVA; McK 243500) is 
an autosomal recessive disorder caused by a 
deficiency of isovaleryl CoA dehydrogenase 
(Sweetman and Williams, 1995). Hydrolysis of 
isovaleryl-CoA leads to the accumulation of toxic 
isovaleric acid in plasma and to a strongly 
increased level of the isovalerylglycine (IVG) 
conjugate in urine. 
The acute neonatal form of the disease is 
characterized by early onset, usually within the 
first few days of birth, of several features such as 
feeding refusal, vomiting, dehydration, lethargy 
and coma, which is often fatal. Dietary restric- 
tion of protein intake and administration of gly- 
cine and carnitine diminish the recurrence of 
episodes of severe ketoacidosis, but this may not 
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always be prevented, especially following respira- 
tory infections. The diagnosis of IVA, which is 
often already indicated by the typical 'sweaty 
feet' odour, is established by the demonstration 
of high concentrations of IVG and 
3-hydroxyisovaleric acid (3-HIVA) in urine 
(Sweetman and Williams, 1995). The diagnosis 
may be c o n h e d  by direct assay of isovaleryl 
CoA dehydrogenase in fibroblasts (Hyman and 
Tanaka, 1986; Frerman and Goodman, 1985) or 
indirectly by monitoring the incorporation of 
[ 1 -'4C]isovaleric acid ([14C]Iva) into macro- 
molecules (Dubiel et al., 1983). 
Prenatal diagnosis of IVA was first reported in 
two pregnancies at risk by Hine et al. (1986) and 
more recently in a third case by Dumoulin et al. 
(1991), both by measurement of metabolites in the 
amniotic fluid and of ['4C]Iva incorporation in 
cultured amniocytes. First-trimester diagnosis by 
chorionic villus sampling (CVS) has not yet been 
reported. 
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We report here our experience in a consecutive 
series of 24 prenatal diagnoses by metabolite 
measurement in amniotic fluid and ['4C]Iva incor- 
poration in chorionic villi (Cv), cultured CV cells, 
and amniocytes. The series includes the first pre- 
natal diagnosis by CVS of an affected fetus in the 
1 1 th week of pregnancy and also the first report of 
a strongly increased level of IVG in amniotic fluid 
in the 12th week. 
CASE REPORTS 
Prenatal analyses were performed in 24 at-risk 
pregnancies of 17 couples from nine different 
countries. All mothers had given birth to at least 
one previous child with IVA; the diagnoses had 
been established locally by clinical features and 
metabolite analysis in urine, showing strong eleva- 
tions of IVG and 3-HNA concentrations. In 
patients' skin fibroblasts from eight of the families, 
the diagnosis was c o b e d  by investigation of the 
leucine degradation pathway, as described below. 
CVS and amniocentesis in Dutch cases were 
performed at the University Hospital, Dijkzigt, 
Rotterdam (three at-risk cases and most of the 
controls) and in Groningen (one case). In all the 
other cases, fresh CV in culture medium, cultured 
CV cells, or unprocessed amniotic fluid (AF) 
samples were sent, usually by air, within 24 h to 
Rotterdam; cell-free AF was sent frozen in dry ice 
to Amsterdam either from Rotterdam or directly 
from the original place of sampling. 
MATERIALS AND METHODS 
Chorionic villi and cell cultures 
CV were sampled in the 10th-12th week of 
pregnancy, separated from maternal decidua and 
mucus, selected, and transported in culture 
medium to the laboratory. Upon arrival at our 
laboratory, the CV were inspected again under a 
microscope. CV cells, AF cells, and skin fibroblasts 
were cultured in Ham's F10 medium with 15 per 
cent fetal calf serum and antibiotics in a humidified 
CO, (3 per cent) incubator. CV cells and amnio- 
cytes from the second or third passage were used 
for the assays. In each assay of CV or cultured CV 
cells or amniocytes from pregnancies at risk, nor- 
mal control CV or cultures of corresponding cell 
types were included; moreover, all assays included 
normal control fibroblasts and at least one cell 
strain from a previously studied IVA patient. 
Control CV were taken from abundant samples 
obtained for chromosome analysis only. 
[I-'4C]Isovaleric acid incorporation into 
macromolecules 
The activity of isovaleryl CoA dehydrogenase 
was indirectly assayed by the so-called macro- 
molecular labelling test described by Dubiel et al. 
(1983), measuring the incorporation of [I4C]Iva in a 
macromolecular fraction in intact cultured cells or 
CV. For triplicate assays of cell cultures, 2.5 x lo5 
cells were seeded in three dishes (35 mm diameter). 
For CV samples, six dishes were provided with 
several small villus fragments (2-5mg per dish). 
After overnight incubation, the culture medium was 
replaced by 2 mVdish medium containing 1 pCilml 
[l-'4C]isovaleric acid (50-60 mCilmmo1; ARC, 
St Louis, U.S.A.) and 2pCilml ~-[4,5-~H]leucine 
(1 30-1 90 Cilmmol; Amersham). The dishes were in- 
cubated for 48 h at 37°C. Cells were harvested by 
trypsinization (0.25 per cent), taken up in culture 
medium, centrifuged for 5 min at loo0 rpm, and the 
pellets washed twice in phosphate-buffered saline, 
pH 7.4 (PBS). Ice-cold trichloroacetic acid (TCA; 
0.5 ml 5 per cent) was added to each pellet, which 
was then suspended vigorously and kept on ice for 
lOmin and centrifuged for 1Omin at 3000rpm. 
After a second TCA precipitation step, the pellet 
was suspended in 200pl of 1 N NaOH and kept at 
room temperature for 30min. CV samples were 
treated similarly, except that they were washed at 
least four times in PBS. After all PBS washings and 
TCA precipitations, CV were not pelleted by cen- 
trifugation, but by removing the fluids with Pasteur 
pipettes. For complete solubilization, the CV 
'precipitates' were kept in 200pl of 1 N NaOH for 
30min at 60°C. Aliquots of 1OOpl of the resulting 
solutions were used for counting radioactivity in 
5 m l  of Hionic (Packard). The remainder of the 
solutions was used for protein assay using the BCA 
method (Smith et al., 1985). 
The incorporation of I4C in all tests is expressed 
as dpm, both per pg protein and per dpm 3H from 
[3H]leucine. However, as more variation is found 
when 14C incorporation is expressed as dpdpg,  all 
results in this paper are presented as the ratios of 
dpm I4U3H. 
Determination of isovalerylglycine in amniotic fluid 
The quantitation of IVG in amniotic fluid super- 
natant was performed by stable isotope dilution 
gas chromatographylmass spectrometry according 
to the procedure of Hine et al. (1986). 
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Table I+'4C]Isovaleric acid incorporation in cells of isovaleric acidaemia patients and 
controls 
Controls Isovaleric acidaemia patients 
l4CI3H ratio* ''C/3H ratio* Percentaget 
Range and Range and Range and 
mean f SD mean f SD mean f SD 
Fibroblasts 
24 controls 
Control 1 
(7 assays) 
Control 2 
(8 assays) 
Chorionic villi 
8 controls 
C V cell 
9 controls 
Amniocytes 
18 controls 
1 9-7 1 
3 3 f  12 
13-52 
2 7 f  13 
1 8 4 9  
3 1 f  9 
105-223 
178 f 40 
10-69 
35 f 22 
15-74 
44f 18 
Fibroblasts 
16 patients 
Patient 0 
(1 7 assays) 
Chorionic villi 
Case I$ 
C V cells 
Case 1 
Case 6 
Amniocytes 
Case 1 
Case 6 
Case 15 
1.5-5.7 
3.6 f 1.2 
14-5.5 
2.3 f 1.3 
Ratio 
7.2 
3.5 
5.5 
1.8 
4-6 
2.2 
6-17 
11 .2f2 .9  
5-17 
10.3 f 4.0 
Percentage 
3.3 
5.5 
11.5 
3.8 
10.0 
2,7 
*Ratio of dpm 14U3H x lo3 incorporated per 48 h from [l-'4C]isovaleric acid and [3H]leucine, 
t['4C]Isovaleric acid incorporation ('4C/3H ratio) in patients as a percentage of intra-assay controls. 
$Case numbers as in Table 11. 
respectively. 
RESULTS 
[14C]Isovaleric acid incorporation in cells from 
isovaleric acid acidaemia patients and controls 
The [14C]Iva incorporation test has been applied 
for more than 10 years without essential method- 
ological changes. In all assays cultured fibroblasts 
of control individuals and IVA patients were 
included. Table I shows the results from this whole 
period for 24 different control fibroblast strains 
-and for two other controls which have been repeat- 
edly tested (seven and eight times, respectively). 
The ranges for the two repeatedly tested cell strains 
are not very different from the ranges for the 24 
Merent controls. By contrast, triplicates for each 
cell strain within one assay show variations of no 
more than a few per cent. These results suggest 
that the inter-assay variation (including culture 
conditions) is greater than the variation between 
individuals. 
A similar conclusion may be drawn from the 
results for IVA patients' cell strains (Table I). One 
cell strain (patient 0) was used as the standard 
patient control in 17 different assays: the range of 
the incorporation level, the mean, and the stan- 
dard deviation (SD) were not different from the 
results for 16 different IVA patients. The incorpo- 
ration levels for patients' cell strains are reduced to 
approximately 10 per cent of the level of incorpo- 
ration in controls. The inter-assay variation is 
somewhat diminished when the incorporation in 
IVA patients is expressed as a percentage of the 
level in one or two intra-assay controls (Table I, 
right-hand column); the mean level in patients 
remains at approximately 10 per cent. There was 
no consistent evidence that some IVA cell lines 
have a higher or lower incorporation rate than 
others. 
Cultured CV cells and amniotic fluid cells from 
normal control pregnancies had similar ''C/3H 
incorporation ratios to those of cultured fibro- 
blasts. However, the incorporation ratio in uncul- 
tured CV is significantly higher than in cultured 
cells (Table I). Results on CV cells and amniocytes 
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Table 11-Prenatal diagnoses for isovaleric acidaemia in 24 at-risk pregnancies by (indirect) 
enzyme analysis and metabolite measurement 
[‘4C]Iva incorporation 
% of intra-assay control(s) Prenatal 
Iva-glycine diagnosis 
Case* Proband CV CVcells AFcells (nmoYI)AF andTOPt 
First trimester 
(10-12 weeks) 
1. Li 94 NL 
2. Br 90 NL 
3. Mo 91 I 
4. Bi 93 CH 
5. Te 92 D 
6. De 89 F 
Second trimester 
(1417 weeks) 
7 .  Sa 82 NL 
8. Sa 84 NL 
9. Su 84 CS 
10. Su 86 CS 
11. Ha 89 F 
12. Su 91 ISR 
13. Ov 91 ISR 
14. Ov 93 ISR 
15. Te 94 D 
16. Ve 88 E 
17. C1 89 GB 
18. Ov 90 ISR 
19. Du 91 F 
20. De 92 F 
21. Gii 93 D 
22. Ba 93 E 
23. Su 94 ISR 
24. Be 94 GB 
3 6 4 1631 (12 weeks) 
79 - 65 19 (16weeks) 
143 145 - - 
124 117 - - 
- 10 9 4323 (16 weeks)ll 
- - 54 - 
118 <507 
122 c 5 q  
59 50 
99 80 
63 5 
284 19 
100 10 
158 19 
10 
33 
3 6358 (16 weeks) 
12 
24 
112911 (18 weeks) 
29 
17 
28 
48 
*Initials, year, and origin (country) of samples. 
?Termination of pregnancy (+) or born and not affected. 
$Fibroblasts of proband in family; case 1 fetus after TOP. 
§Multiple pregnancies of the same mother investigated. 
//Cases 6 and 19 were also studied in Lyon (Dumoulin er al., 1991). 
VCases 7 and 8, qualitative metabolite analysis. 
from affected pregnancies are indicated in the 
right-hand part of Table I and will be elucidated 
below. 
First-trimester analysis of chorionic villi and 
amniotic fluid 
Six pregnancies at risk were studied in the first 
trimester. In cases 1-4, listed in Table 11, CV were 
directly analysed after arrival from our hospital 
(cases 1 and 2) or from Genova, Italy (case 3) and 
Ziirich, Switzerland (case 4). In each case, six small 
portions of CV fragments were selected and tested 
separately as described in the Materials and 
Methods section. Six to 12 small portions of CV 
fragments from two control pregnancies (at risk 
for chromosome aberrations) served as intra-assay 
controls; in cases 3 and 4, one of the two control 
samples was sent together with the at-risk sample 
from abroad, whde the second sample was from 
our own centre. The results of all separate mea- 
surements are presented in Fig. l .  All CV frag- 
ments from pregnancy 1 showed severe deficiency 
of incorporation of radiolabel from [14C]Iva, while 
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Fig. I-[ I-'4C]Isovaleric acid incorporation in macromolecules 
in intact chorionic villi from four pregnancies at risk (0) and 
eight controls (7; A). Three to six samples from each preg- 
nancy were separately investigated 
a high incorporation of [3H]leucine indicated nor- 
mal protein synthetic activity in these villus frag- 
ments (i.e., the l4CI3H ratio in case 1 is very low 
compared with the controls, Fig. 1). The mean 
incorporation ratio for the villi from the pregnancy 
at risk was 3 per cent of the mean ratio for the 
controls. An unequivocal diagnosis of an affected 
fetus could be made 3 days after CVS. At termi- 
nation at the end of the 12th week of pregnancy, 
amniotic fluid was sampled to allow metabolite 
measurements in the fluid at that early stage. The 
concentration of NG was 1631 nmol/l, which is 
50-100 times the control level (controls at 12-13 
weeks, n=3; 1-54 nmol/l). Further confirmation of 
the prenatal diagnosis was obtained by ['4C]Iva 
incorporation studies in three types of cultured 
cells: CV cells which had been cultured from the 
original CV sample, amniotic fluid cells, and 
fibroblasts grown from fetal skin; the results are 
summarized in Tables I and I1 (case 1). 
The direct analyses of CV in cases 2 4  are shown 
in Fig. 1 and Table I1 as well: normal incorpora- 
tion levels were confirmed in cultured CV cells in 
cases 3 and 4, and as CV cells did not grow well, by 
amniocentesis in case 2 (Table II). In cases 5 and 6, 
we were consulted only after CVS. Cultured CV 
cells in case 5 exhibited a slightly reduced, but not 
deficient, level of ['4C]Iva incorporation; as the 
fetus was female, the presence of maternal cells 
could not be excluded and amniocentesis was 
recommended, but this was not carried out. As 
predicted, the children born from pregnancies 2-5 
were not affected. In case 6, a clear deficiency of 
['4C]Iva incorporation was demonstrated in the 
CV cells, similar to the level in fibroblasts of the 
proband (Tables I and 19. These results were 
conlirmed by the demonstration of a highly 
elevated concentration of N G  in amniotic fluid 
and the deficiency of ['4C]Iva incorporation in the 
amniocytes (Tables I and 11). 
Second-trimester analyses of amniotic fluid and 
amniocytes 
In 18 pregnancies at risk, prenatal analyses were 
carried out only after amniocentesis in the 14th- 
17th week since CVS in these pregnancies was not 
(yet) possible or not desirable. In all pregnancies 
the N G  concentration was measured, which was 
followed by ['4C]Iva incorporation testing of 
amniocytes in the nine cases in which complete 
amniotic fluid was sampled or sent to Rotterdam; 
in nine other cases, only cell-free amniotic fluid 
was sent to Amsterdam. 
In two cases (15 and 19, Table II), very high 
IVG concentrations were measured: roughly 250 
and 40 times the mean control level, respectively. 
These findings allowed the definitive diagnosis of 
an affected fetus. Subsequent investigation of cul- 
tured amniocytes of case 15 showed severely defi- 
cient [l4C]1va incorporation (3 per cent of the 
intra-assay control, Tables I and 11); the diagnosis 
in case 19 was in agreement with parallel studies in 
Lyon (Table 11, footnote 11). 
In the 16 remaining pregnancies at risk, a non- 
affected fetus was indicated by IVG concentrations 
in the normal range (at 14-17 weeks, n=80; 
1-66 nmol/l), or only slightly above that range 
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(case lo), and by normal [14qIva incorporation 
when amniocytes were available. None of the 
children born from these 16 pregnancies was 
affected with IVA. 
DISCUSSION 
Prenatal diagnosis of IVA is possible by the 
measurement of metabolites in amniotic fluid and 
by monitoring the leucine catabolic pathway in CV 
or amniotic fluid cells. Extremely high IVG con- 
centrations were demonstrated in the amniotic 
fluid of three not previously reported pregnancies 
with a fetus affected with IVA. In two of these 
cases, at 16 weeks of gestation the IVG concentra- 
tion was 200-300 times the mean control level, 
which was considerably higher than the levels in 
the three previously reported cases, which, how- 
ever, still exhibited a 30- to 60-fold elevated con- 
centration (Hine et al., 1986; Dumoulin et al., 
1991). In one other affected pregnancy, we demon- 
strated a very high IVG concentration in the 
amniotic fluid as early as 12 weeks of gestation. In 
all non-affected pregnancies, N G  concentrations 
were in the normal control range (1 6 cases) or only 
slightly higher (one case). The distinction between 
the N G  levels present in the six affected pregnan- 
cies reported up to now and those in pregnancies 
at risk with unaffected fetuses is extremely great. 
There is no evidence that heterozygosity of either 
the fetus (a 2/3 chance) or the mother (all cases) 
has a significant iduence on the IVG concentra- 
tion in the fluid. So, measurement of IVG (and 
possibly 3-HIVA) in amniotic fluid appears to be a 
reliable method for the prenatal diagnosis of IVA, 
which could be applied as early as 12 weeks of 
gestation. 
Whenever complete amniotic fluid or cultured 
amniocytes were received (12 cases), [14C]Iva 
incorporation tests were done and the results were 
in accordance with the metabolite measurements. 
[ 14C]Iva incorporation in amniocytes was deficient 
in the three affected cases, i.e., <lo per cent of 
control values, which was clearly distinct from the 
levels in all other pregnancies with a homozygous 
normal or heterozygous fetus. The nature of the 
apparent residual incorporation, which we also 
found in skm fibroblasts of IVA patients, is not 
known but could well represent the contribution of 
other acyl CoA dehydrogenases (Hyman and 
Tanaka, 1986). The results indicate that [14C]Iva 
incorporation in amniocytes provides a reliable 
adjunctive method for prenatal diagnosis, but 
the disadvantage is that cell cultivation and 
analysis take at least 3 weeks following amnio- 
centesis. A much earlier diagnosis can be 
achieved by direct analysis of the fresh, un- 
cultured CV, which may be sampled in the 10th- 
12th week of pregnancy. 
Tests monitoring metabolic pathways in intact 
CV have been successfully applied for the prenatal 
diagnosis of several disorders such as citrulli- 
naemia and maple syrup urine disease (Kleijer et 
al., 1984, 1985). The incorporation of radiolabel 
from [14C]Iva in proteins requires passage through 
the leucine catabolic pathway, part of the tricar- 
boxylic acid cycle, and via amino acids and protein 
synthesis. The high level of I4C incorporation in 
the present study of CV shows that all these steps 
are actively functioning in CV from controls and 
from the three at-risk pregnancies with normal 
outcome. By contrast, the CV from an affected 
fetus exhibited an almost complete deficiency of 
[14C]Iva incorporation. Although the present case 
represents the first diagnosis of IVA within the 
first-trimester, the results suggest that the method 
used allows a reliable diagnosis before 13 weeks 
and thus termination of pregnancy by suction 
curettage. The use of cultured CV cells also allows 
a reliable diagnosis, as was shown in two cases 
here, but the disadvantage-besides the delay 
caused by cell cultivation-is that the risk of 
maternal cell growth is not neghgible (e.g., 1-2 per 
cent; Roberts et al., 1988; our unpublished results). 
This means that the diagnosis can only be conclu- 
sive if an unequivocal deficiency is shown in the 
cultured cells or, in the case of normal results, if 
the fetus is male, so that the absence of maternal 
cells can be demonstrated. 
We conclude that the best strategy for an early, 
rapid, and reliable diagnosis is the direct analysis 
of intact CV at 10-12 weeks, which leaves the 
option of subsequent testing of cultured CV cells 
or of amniocentesis and measurement of IVG in 
the presumably rare case of equivocal results. 
Alternatively, amniocentesis can be done at 
14-16 weeks, or perhaps even earlier, to achieve a 
conclusive diagnosis within a few days based on 
metabolite measurements in the fluid. Confirma- 
tion of the diagnosis by [14C]Iva incorporation 
testing of cultured amniocytes seems good practice 
but should neither delay a termination of preg- 
nancy in the case of a high IVG concentration, nor 
delay reassurance of the parents in the case of a 
normal IVG level. 
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